Under a tenth of individuals who could benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it publishes its first recommendations on the medications.
Considering over a billion people worldwide currently living with obesity, it is calling for broader and more equitable access to these injectable treatments.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with thorough and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant obstacles to universal availability to the jabs that can assist patients in reducing considerable weight, says the body.
Skinny Jab Shortage
Even under the current most favorable outlook, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of eligible patients, per the WHO.
The recommendation urges countries and companies to widen access, through strategies like licensing agreements.
Exclusive production rights on a key compound – the primary component of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Jabs Function
These medications imitate a biological compound to delay gastric emptying, reduce hunger and enhance satiety so individuals eat less.
Individuals typically see weight reduction after several weeks of starting on the weekly injections.
Research indicates patients may see weight return within a year of discontinuing the treatment, when their usual food cravings resume.
Being overweight or obese raises your chance for contracting medical conditions, such as type 2 diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
